Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation

European Respiratory Journal

Volumn 37, Issue 3, 2011, Pages 624-631

  Porta, R ^a   Sanchez Torres J M ^b   Paz Ares, L ^c   Massuti B ^d   Reguart, N ^e   Mayo, C ^f   Lianes, P ^g   Queralt, C ^f,h   Guillem, V ⁱ   Salinas, P ^j   Catot, S ^k   Isla, D ^l   Pradas, A ^h   Gurpide A ^m   De Castro, J ⁿ   Polo, E ^o   Puig, T ^a,p   Taron M ^f,i   Colomer, R ^b   Rosell, R ^f,i  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f INSTITUT UNIVERSITARI DEXEUS   (Spain)

^g HOSPITAL DE MATARÓ   (Spain)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁱ Dept of Medical Oncology   (Spain)

^j Hospital Sanitas La Zarzuela   (Spain)

^k Althaia   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^m UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o Hospital Ernest Lluch   (Spain)

^p UNIVERSITY OF GIRONA   (Spain)

more..

Author keywords

EGFR; Metastases; Mutation screening; Nonsmall cell lung cancer; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ACNE; ADULT; ALOPECIA; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONJUNCTIVITIS; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EXON; FEMALE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SKIN DISEASE; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952268212     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00195609     Document Type: Article

References (28)

1. Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474-1480. (Pubitemid 19089037)
2. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-751. (Pubitemid 27181303)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. (Pubitemid 41058344)
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl JMed 2004; 350: 2129-2139. (Pubitemid 38637993)
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
7. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006; 9: 485-495. (Pubitemid 43832191)
8. Politi K, Zakowski MF, Fan PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510. (Pubitemid 43830656)
9. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346. (Pubitemid 40425952)
10. Rosell R, Taron M, Reguart N, et al. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 2006; 12: 7222-7231. (Pubitemid 46095393)
11. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
13. Common Terminology Criteria for Adverse Events version 3.0 www.ctep.cancer.gov/reporting/ctc Date last accessed January 12, 2011. Date last updated September 7, 2010.
14. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
15. Serizawa T. Radiosurgery for metastatic brain tumors. Int J Clin Oncol 2009; 14: 289-298.
16. Das AK, Sato M, Story MD, et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006; 66: 9601-9608. (Pubitemid 44623659)
17. Gow CH, Chien CR, Chang YL, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008; 14: 162-168.
18. Adamo V, Franchina T, Adamo B, et al. Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. Ann Oncol 2006; 17: Suppl. 2, ii73-75.
19. Colomer R, Cosos D, Del Campo JM, et al. Brain metastases from breast cancer may respond to endocrine therapy. Breast Cancer Res Treat 1988; 12: 83-86.
20. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41: 227-231.
21. Namba Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004; 6: 123-128. (Pubitemid 39440210)
22. Poon AN, Ho SS, Yeo W, et al. Brain metastasis responding to gefitinib alone. Oncology 2004; 67: 174-178. (Pubitemid 39482687)
23. Takahashi H, Ohrui T, Ebihara S, et al. Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer 2004; 43: 371-372. (Pubitemid 38224161)
24. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-1047. (Pubitemid 39089780)
25. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005; 103: 2344-2348. (Pubitemid 40686581)
26. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009; 65: 80-84.
27. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4: 1415-1419.
28. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247. (Pubitemid 41103678)